Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

J Infect Dis. 2003 Oct 15;188(8):1171-80. doi: 10.1086/378412. Epub 2003 Sep 30.

Abstract

We determined immune cross-recognition and the degree of Tat conservation in patients infected by local human immunodeficiency virus (HIV) type 1 strains. The data indicated a similar prevalence of total and epitope-specific anti-Tat IgG in 578 serum samples from HIV-infected Italian (n=302), Ugandan (n=139), and South African (n=137) subjects, using the same B clade Tat protein that is being used in vaccine trials. In particular, anti-Tat antibodies were detected in 13.2%, 10.8%, and 13.9% of HIV-1-infected individuals from Italy, Uganda, and South Africa, respectively. Sequence analysis results indicated a high similarity of Tat from the different circulating viruses with BH-10 Tat, particularly in the 1-58 amino acid region, which contains most of the immunogenic epitopes. These data indicate an effective cross-recognition of a B-clade laboratory strain-derived Tat protein vaccine by individuals infected with different local viruses, owing to the high similarity of Tat epitopes.

Publication types

  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • AIDS Vaccines
  • Adolescent
  • Adult
  • Amino Acid Sequence
  • Conserved Sequence*
  • Cross Reactions
  • Cross-Sectional Studies
  • Epitope Mapping
  • Female
  • Gene Products, tat / chemistry
  • Gene Products, tat / genetics*
  • Gene Products, tat / immunology*
  • HIV Antibodies / blood*
  • HIV Infections / immunology
  • HIV Infections / virology
  • HIV-1 / classification*
  • HIV-1 / genetics
  • HIV-1 / immunology
  • Humans
  • Italy
  • Male
  • Middle Aged
  • Molecular Sequence Data
  • Phylogeny
  • Sequence Analysis, DNA
  • South Africa
  • Uganda
  • tat Gene Products, Human Immunodeficiency Virus

Substances

  • AIDS Vaccines
  • Gene Products, tat
  • HIV Antibodies
  • tat Gene Products, Human Immunodeficiency Virus

Associated data

  • GENBANK/AY193980
  • GENBANK/AY193981
  • GENBANK/AY193982
  • GENBANK/AY193983
  • GENBANK/AY193984
  • GENBANK/AY193985
  • GENBANK/AY193986
  • GENBANK/AY193987
  • GENBANK/AY193988
  • GENBANK/AY193989
  • GENBANK/AY193990
  • GENBANK/AY193991
  • GENBANK/AY193992
  • GENBANK/AY193993
  • GENBANK/AY193994
  • GENBANK/AY193995
  • GENBANK/AY193996
  • GENBANK/AY193997
  • GENBANK/AY193998
  • GENBANK/AY193999
  • GENBANK/AY194000
  • GENBANK/AY194001
  • GENBANK/AY194002
  • GENBANK/AY194003
  • GENBANK/AY194004
  • GENBANK/AY194005
  • GENBANK/AY194006
  • GENBANK/AY194007
  • GENBANK/AY194008
  • GENBANK/AY194009
  • GENBANK/AY194010
  • GENBANK/AY194011
  • GENBANK/AY194012
  • GENBANK/AY194013
  • GENBANK/AY194014
  • GENBANK/AY194015
  • GENBANK/AY194016
  • GENBANK/AY194017
  • GENBANK/AY194018
  • GENBANK/AY194019
  • GENBANK/AY194020
  • GENBANK/AY194021
  • GENBANK/AY194022
  • GENBANK/AY194023
  • GENBANK/AY194024
  • GENBANK/AY194025
  • GENBANK/AY194026
  • GENBANK/AY194027
  • GENBANK/AY194028
  • GENBANK/AY194029
  • GENBANK/AY194030
  • GENBANK/AY194031
  • GENBANK/AY194032
  • GENBANK/AY194033
  • GENBANK/AY194034
  • GENBANK/AY194035
  • GENBANK/AY194036
  • GENBANK/AY194037
  • GENBANK/AY194038
  • GENBANK/AY194039
  • GENBANK/AY194040
  • GENBANK/AY194041
  • GENBANK/AY194042
  • GENBANK/AY194043
  • GENBANK/AY194044
  • GENBANK/AY194045
  • GENBANK/AY194046
  • GENBANK/AY194047
  • GENBANK/AY194048
  • GENBANK/AY194049
  • GENBANK/AY194050
  • GENBANK/AY194051
  • GENBANK/AY194052
  • GENBANK/AY194053